RELIEF-AD: Real-world effectiveness of mometasone furoate in itch reduction in pediatric atopic dermatitis
Indian Journal of Skin Allergy · 01.10.2026 · 5 · 199-200
DOI: 10.25259/ijsa_31_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, online erschienen am 01.10.2026. Verfasst von Abhishek De und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Dear Editor, Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by dryness, barrier dysfunction, and persistent itch, causing sleep disturbance, psychosocial burden, and impaired quality of life for both children and caregivers.[1] Dry skin lowers the itch threshold through increased intraepidermal nerve fibers and sensory nerve sensitization mediated by keratinocyte-derived interleukin (IL)-33.This makes the skin highly responsive to mechanical and chemical itch triggers.Scratching further damages the skin barrier, allowing allergen penetration and promoting type 2 inflammation.T-helper 2(Th2) cytokines, including IL-4, IL-13, and IL-31, amplify sensory nerve sensitization, creating a self-perpetuating itch-scratch cycle that drives disease burden.Therefore, effective itch control is central to AD management.[2] Topical corticosteroids inhibit T-cell proliferation and reduce pro-inflammatory cytokine production responsible for itch [3] and hence remain the first-line anti-inflammatory therapy.[4] Among available agents, mometasone furoate is a mid-potent topical corticosteroid with strong glucocorticoid-receptor affinity, once-daily dosing, and a favorable therapeutic index when used appropriately.[5] However, real-world evidence focused on patient-perceived itch reduction in Indian children treated with mometasone furoate is limited.We report findings from a large, multicenter, retrospective, real-world study conducted across India evaluating patientreported outcomes following short-term use of mometasone furoate 0.1% cream in pediatric patients with mild to moderate AD.Improvement in itch was assessed using patient-reported outcomes on a 10-point scale.Scores of 8-10 were categorized as clear/almost clear response, scores of 1-3 as inadequate response, and intermediate scores (4-7) represented partial to moderate symptom control.Time to symptom improvement and safety outcomes
Zitieren
APA
De, A., Dhoot, D., & Gaikwad, S. P. (2026). RELIEF-AD: Real-world effectiveness of mometasone furoate in itch reduction in pediatric atopic dermatitis. Indian Journal of Skin Allergy, 5, 199-200. https://doi.org/10.25259/ijsa_31_2026
Vancouver
De A, Dhoot D, Gaikwad SP. RELIEF-AD: Real-world effectiveness of mometasone furoate in itch reduction in pediatric atopic dermatitis. Indian Journal of Skin Allergy. 2026;5:199-200. doi:10.25259/ijsa_31_2026
BibTeX
@article{De2026,
author = {De, Abhishek and Dhoot, Dhiraj and Gaikwad, Sheela Pralhad},
title = {RELIEF-AD: Real-world effectiveness of mometasone furoate in itch reduction in pediatric atopic dermatitis},
journal = {Indian Journal of Skin Allergy},
year = {2026},
volume = {5},
pages = {199--200},
doi = {10.25259/ijsa_31_2026}
}
EUVIMED